Exco InTouch Achieves Quality Milestone with ISO9001:2008 Certification - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Exco InTouch Achieves Quality Milestone with ISO9001:2008 Certification

Source: Company News Release
Exco InTouch, the leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, today announced that it has been approved to ISO9001:2008 by Lloyd’s Register Quality Assurance (LRQA), the world’s leading provider of independent assessment services.

This milestone certification has been awarded to Exco InTouch in recognition that the company has developed and implemented a quality management system built around processes of the highest standards and which meets or exceeds its customers’ requirements, whilst maximizing continual improvement.

The ISO9001:2008 certification underwrites the superior quality of Exco InTouch’s service delivery processes, making the company the only electronic Clinical Outcomes Assessment (eCOA) provider to comply with ISO9001:2008 as well as the data privacy and security standards: Safe Harbor, EU Data Protection and HIPAA, which are essential when using a BYOD (Bring Your Own Device) approach in clinical and healthcare settings.

Tim Davis, CEO and founder of Exco InTouch commented: “We are delighted to have received this important certification. The capability underlines our commitment to quality and our ability to provide best in class services for our customers whilst marking us out as a gold standard provider in our field”.

Mark Wright, Head of Quality Assurance at Exco InTouch commented; “Quality of service is a key driver for us at Exco InTouch and we are very pleased to have been approved to ISO9001:2008 in recognition of the very high standard of products and services that we provide in mobile and digital technology data capture and patient engagement solutions. We are achieving ever increasing customer service levels to meet the needs of our clients head on and we are proud to have been formally recognized in this regard.”

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 203 6740 or e-mail: t.jervis@defacto.com.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here